Santhera Pharmaceuticals, which manufacturers vamorolone – the steroid alternative which the DRF was involved in funding at the Phase 1 stage – has announced it has licensed vamorolone to Catalyst Pharmaceuticals in North America. Catalyst Pharmaceuticals will manage and distribute vamorolone in the region.

Click here to read Santhera’s press release for further information.